Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
Submitted by
admin
on July 19, 2018 - 11:20am
Source:
CP Wire
News Tags:
Takeda
vedolizumab
ulcerative colitis
Entyvio
Headline:
Takeda Drug Achieves Primary Endpoint of Clinical Remission in Moderately to Severely Active Ulcerative Colitis
snippet:
A statistically significant proportion of patients achieved clinical remission at week 52 compared to placebo
Vedolizumab is a humanized monoclonal antibody specifically designed to mediate inflammation in UC and CD patients
In a previous study, Vedolizumab, achieved superior results in mucosal healing vs TNFα-antagonist therapy
Do Not Allow Advertisers to Use My Personal information
